Weathering the storm: Another biotech braves Covid-19 in upsized IPO
Zentalis isn’t the only biotech to defy expectations as financial markets across the globe roil from the shock of the coronavirus pandemic. Keros Therapeutics has managed to execute an IPO, hitting the top end of its pricing range and selling more shares than originally envisioned, as it shepherds its lead drug into mid-stage development.
The Lexington, Massachusetts-based company’s pipeline of drugs target a family of proteins called transforming growth factor-beta (TGF-β), signaling pathways that regulate blood cell and platelet production, and growth, repair, and maintenance of muscle and bone.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.